このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Sino Biopharmaceutical マネジメント

マネジメント基準チェック /14

Sino Biopharmaceutical'sの CEO はEric S. Y. Tseで、 Jul2022年に任命され、の在任期間は 1.92年です。の年間総報酬はCN¥ 49.69Mで、 45.4%給与と54.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の22.11%を直接所有しており、その価値はHK$ 11.11B 。経営陣と取締役会の平均在任期間はそれぞれ1.4年と9.1年です。

主要情報

Eric S. Y. Tse

最高経営責任者

CN¥49.7m

報酬総額

CEO給与比率	45.4%
CEO在任期間	1.9yrs
CEOの所有権	22.1%
経営陣の平均在職期間	1.4yrs
取締役会の平均在任期間	9.1yrs

経営陣の近況

Recent updates

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

May 21

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Dec 18

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Dec 02

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

Nov 17

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Aug 30

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

May 26

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Apr 20

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Feb 09

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Nov 11

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Oct 24

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Jul 08

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Apr 28

An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued

Jan 22

Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet

Dec 03

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Oct 19

Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02

Sep 03

CEO報酬分析

Sino Biopharmaceutical の収益と比較して、Eric S. Y. Tse の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	CN¥50m	CN¥23m	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	n/a	n/a	CN¥2b
Sep 30 2022	n/a	n/a	CN¥5b
Jun 30 2022	n/a	n/a	CN¥8b
Mar 31 2022	n/a	n/a	CN¥14b
Dec 31 2021	CN¥23m	CN¥6m	CN¥15b
Sep 30 2021	n/a	n/a	CN¥12b
Jun 30 2021	n/a	n/a	CN¥10b
Mar 31 2021	n/a	n/a	CN¥4b
Dec 31 2020	CN¥25m	CN¥7m	CN¥3b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥3b
Mar 31 2020	n/a	n/a	CN¥3b
Dec 31 2019	CN¥6m	CN¥870k	CN¥3b

報酬と市場: Eric S. Y.の総報酬 ($USD 6.85M ) は、 Hong Kong市場 ($USD 899.42K ) の同規模の企業の平均を上回っています。

報酬と収益: Eric S. Y.の報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。

CEO（最高経営責任者

Eric S. Y. Tse (28 yo)

1.9yrs

在職期間

CN¥49,691,000

報酬

Mr. Eric S. Y. Tse serves as an Executive Director at Sino Biopharmaceutical Limited since October 23, 2019 and serves as its Chief Executive Officer since July 28, 2022. Mr. Tse joined Sino Biopharmaceuti...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Y. Y. Tse	Executive Chairwoman of the Board	9yrs	CN¥49.69m	0.033% CN¥ 16.0m
Eric S. Y. Tse	CEO & Executive Director	1.9yrs	CN¥49.69m	22.11% CN¥ 10.8b
Ping Tse	Founder & Senior Executive Vice Chairman	3.8yrs	CN¥49.53m	9.12% CN¥ 4.5b
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7.2yrs	CN¥43.13m	16.19% CN¥ 7.9b
Zhoushan Tian	Executive Director	no data	CN¥1.91m	データなし
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.41m	1.95% CN¥ 954.7m
Chun Ling Li	Chief Financial Officer	1.4yrs	データなし	データなし
Song Jin	Vice President of Public Affairs	no data	データなし	データなし
Sean Chen	Chief Strategy Officer	1.4yrs	データなし	データなし
Orphanides George	Chief Scientific Advisor of invoX	1.4yrs	データなし	データなし
Chau Ling Yu	Assistant VP & Financial Controller	no data	データなし	データなし
Oi Nin Chan	Company Secretary	8.8yrs	データなし	データなし

1.4yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: 1177の経営陣は経験豊富とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Y. Y. Tse	Executive Chairwoman of the Board	9yrs	CN¥49.69m	0.033% CN¥ 16.0m
Eric S. Y. Tse	CEO & Executive Director	4.7yrs	CN¥49.69m	22.11% CN¥ 10.8b
Ping Tse	Founder & Senior Executive Vice Chairman	3.8yrs	CN¥49.53m	9.12% CN¥ 4.5b
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7.2yrs	CN¥43.13m	16.19% CN¥ 7.9b
Zhoushan Tian	Executive Director	9.2yrs	CN¥1.91m	データなし
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.41m	1.95% CN¥ 954.7m
Zhengfei Lu	Independent Non-Executive Director	18.6yrs	CN¥376.00k	データなし
Dakui Li	Independent Non-Executive Director	19.8yrs	CN¥376.00k	データなし
Lu Fu Zhang	Independent Non-Executive Director	9.2yrs	CN¥376.00k	データなし
Hong Lu	Independent Non-Executive Director	9.2yrs	CN¥342.00k	データなし
Kwok Tung Li	Independent Non-Executive Director	3.5yrs	CN¥376.00k	0.00039% CN¥ 190.9k

9.1yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: 1177の取締役会は経験豊富であると考えられます ( 9.1年の平均在任期間)。

Sino Biopharmaceutical マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Key Executive recently bought HK$34m worth of stock

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

Less than half of directors are independent

Recent updates

Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)"

Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules

Investor sentiment improves as stock rises 18%

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Consensus revenue estimates fall by 13%

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Now 21% undervalued

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Investor sentiment improves as stock rises 16%

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Upcoming dividend of HK$0.02 per share at 2.7% yield

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022)

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023

Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023

Key Executive recently bought HK$34m worth of stock

Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms

Upcoming dividend of HK$0.06 per share at 3.0% yield

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine

Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection)

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203"

Less than half of directors are independent

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Upcoming dividend of HK$0.06 per share

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule

Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial

マネジメント基準チェック /14